1. A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer. Issue 1 (3rd May 2022) Authors: Walford, Geoffrey A.; Duncan, Kelly E.; Hernandez, Moises; Vaddady, Pavan; Hompesch, Marcus; Morrow, Linda; Stoch, S. Aubrey Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 1(2022) Page Start: 125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH. Issue 3 (6th April 2022) Authors: Vilalta, Adrian; Gutiérrez, Julio A.; Chaves, SuZanne; Hernández, Moisés; Urbina, Silvia; Hompesch, Marcus Journal: Endocrinology, diabetes & metabolism Issue: Volume 5:Issue 3(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals. Issue 1 (2nd August 2017) Authors: Garito, Tania; Roubenoff, Ronenn; Hompesch, Marcus; Morrow, Linda; Gomez, Katherine; Rooks, Daniel; Meyers, Charles; Buchsbaum, Monte S.; Neelakantham, Srikanth; Swan, Therese; Filosa, Lee Anne; Laurent, Didier; Petricoul, Olivier; Zakaria, Marjorie Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 1(2018) Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Biosimilar Insulins: Basic Considerations. (January 2014) Authors: Heinemann, Lutz; Hompesch, Marcus Journal: Journal of diabetes science and technology Issue: Volume 8:Number 1(2014:Jan.) Page Start: 6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Biosimilar insulins: current and future perspectives. (November 2015) Authors: Krentz, Andrew J; Hompesch, Marcus Journal: Diabetes management Issue: Volume 5:Number 6(2015) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Issue 11 (13th August 2019) Authors: Pratley, Richard E.; Kang, Jahoon; Trautmann, Michael E.; Hompesch, Marcus; Han, OakPil; Stewart, John; Sorli, Christopher H.; Jacob, Stephan; Yoon, Kun‐Ho Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 11(2019) Page Start: 2429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. Issue 1 (25th June 2021) Authors: Hompesch, Marcus; Kang, Jahoon; Han, OakPil; Trautmann, Michael E; Sorli, Christopher H; Ogbaa, Ike; Stewart, John; Morrow, Linda Journal: BMJ open diabetes research and care Issue: Volume 9:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. Issue 1 (18th January 2022) Authors: Pratley, Richard E; Jacob, Stephan; Baek, Seungjae; Trautmann, Michael E; Hompesch, Marcus; Han, OakPil; Stewart, John; Sorli, Christopher H; Shaunik, Alka; Yoon, Kun-Ho Journal: BMJ open diabetes research and care Issue: Volume 10:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research. (November 2016) Authors: Krentz, Andrew J; Hompesch, Marcus Journal: Biomarkers in medicine Issue: Volume 10:Number 11(2016) Page Start: 1153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials. Issue 3 (21st December 2020) Authors: Beysen, Carine; Schroeder, Patricia; Wu, Eric; Brevard, Julie; Ribadeneira, Maria; Lu, Wei; Dole, Kiran; O'Reilly, Terry; Morrow, Linda; Hompesch, Marcus; Hellerstein, Marc K.; Li, Kelvin; Johansson, Lars; Kelly, Patrick F. Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 3(2021) Page Start: 700 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗